Contrasting Orgenesis (ORGS) & Its Competitors

Orgenesis (NASDAQ:ORGSGet Rating) is one of 937 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Orgenesis to related companies based on the strength of its analyst recommendations, dividends, institutional ownership, valuation, risk, profitability and earnings.

Valuation & Earnings

This table compares Orgenesis and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Orgenesis $35.50 million -$18.05 million 10.03
Orgenesis Competitors $1.83 billion $238.18 million -1.71

Orgenesis’ competitors have higher revenue and earnings than Orgenesis. Orgenesis is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares Orgenesis and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Orgenesis 22.02% 16.12% 10.73%
Orgenesis Competitors -4,343.45% -115.55% -11.42%

Institutional & Insider Ownership

13.0% of Orgenesis shares are owned by institutional investors. Comparatively, 45.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 7.7% of Orgenesis shares are owned by insiders. Comparatively, 14.6% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Orgenesis and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orgenesis 0 0 0 0 N/A
Orgenesis Competitors 6122 20670 43014 858 2.55

As a group, “Pharmaceutical preparations” companies have a potential upside of 114.48%. Given Orgenesis’ competitors higher possible upside, analysts clearly believe Orgenesis has less favorable growth aspects than its competitors.

Volatility & Risk

Orgenesis has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Orgenesis’ competitors have a beta of 0.98, meaning that their average stock price is 2% less volatile than the S&P 500.


Orgenesis competitors beat Orgenesis on 6 of the 10 factors compared.

Orgenesis Company Profile (Get Rating)

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with's FREE daily email newsletter.